Notable Findings on Lebrikizumab in ADmirable Study Assessing Patients with Skin of Color

New data presented at the Revolutionizing Atopic Dermatitis (RAD) Conference highlighted the efficacy of lebrikizumab (Ebglyss) for atopic dermatitis in adult and adolescent patients with skin of color, with improvements observed by the phase 3b ADmirable study’s investigators over 24 weeks.

In a new interview with the HCPLive editorial team, Andrew Alexis, MD, MPH, ADmirable investigator, professor of clinical dermatology, and vice-chair for diversity and inclusion at Weill Cornell Medicine, spoke about his team’s findings on lebrikizumab in patients with skin of color.

He described some of the study's most notable findings, highlighting that the study gives those in the field of dermatology greater insight into what the change over time in pigmentary alterations is when treating with lebrikizumab. Alexis noted that almost 2 thirds of patients in the analysis demonstrated improvement in hyperpigmented lesions on the recently-developed PDCA-Derm assessment.

Alexis further expressed that almost a quarter of patients who had hyperpigmentation improved to their normal skin tone by Week 24 in the ADmirable study.

Alexis has reported advisory/consulting fees from companies including Lilly.

References

1. Alexis A, Moiin A, Waibel J, et al. Efficacy and safety of lebrikizumab in adult and adolescent patients with skin of color and moderate-to-severe atopic dermatitis: final 24-wWeek results from the phase 3b, open-label ADmirable study. Presented at: 2025 Revolutionizing Atopic Dermatitis (RAD) Conference; June 6-7, 2025; Nashville, TN.

2. FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis. September 13, 2024. Accessed June 18, 2025. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-ebglysstm-lebrikizumab-lbkz-adults-and.